Several FcRn inhibitors, which selectively target IgG recycling and thus accelerate IgG clearance, have shown promising results in recent clinical trials for managing immune thrombocytopenia (ITP) and myasthenia gravis [11]. This evidence concerns the gene FCGRT and autoimmune thrombocytopenic purpura.